Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8Stomach Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Pathologic Complete Response 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1HER2 Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1EGFR Positive Non-small Cell Lung Cancer 1Breast Diseases 1Advanced Non-small-cell Lung Cancer 1Advanced Gastric Cancer 1

Interventions

pyrotinib 2Trastuzumab 2Vinorelbine 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × HER2 Positive Breast Cancer × Docetaxel × Clear all
NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡